Latest News from: University of Texas M. D. Anderson Cancer Center

Filters close
Released: 14-Jul-2021 12:15 PM EDT
MD Anderson Research Highlights for July 14, 2021
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease.

13-Jul-2021 10:00 AM EDT
Atezolizumab and Bevacizumab Show Meaningful Responses for Malignant Peritoneal Mesothelioma patients
University of Texas M. D. Anderson Cancer Center

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

Released: 12-Jul-2021 5:00 AM EDT
MD Anderson and Hummingbird Bioscience Announce Strategic Research Collaboration to Advance Innovative Immunotherapies
University of Texas M. D. Anderson Cancer Center

MD Anderson and Hummingbird Bioscience announced a multi-year strategic research collaboration to investigate HMBD-002, Hummingbird's VISTA antagonist antibody, as a novel immunotherapy for cancer.

Newswise: Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
7-Jul-2021 4:50 PM EDT
Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
University of Texas M. D. Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment.

Released: 30-Jun-2021 12:00 PM EDT
MD Anderson Research Highlights for June 30, 2021
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include expanded use of a targeted therapy for a new group of patients with leukemia, molecular studies yielding novel cancer therapeutic targets, insights into radiation therapy resistance and a community intervention to reduce cervical cancer rates.

Newswise: Engineered NK cells can eliminate glioblastoma stem cells
16-Jun-2021 5:35 PM EDT
Engineered NK cells can eliminate glioblastoma stem cells
University of Texas M. D. Anderson Cancer Center

Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.

Released: 16-Jun-2021 11:40 AM EDT
MD Anderson Research Highlights for June 16, 2021
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) infections.

9-Jun-2021 11:05 AM EDT
Combination targeted therapy provides durable remission for patients with chronic lymphocytic leukemia
University of Texas M. D. Anderson Cancer Center

A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.

Released: 9-Jun-2021 6:30 PM EDT
Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations
University of Texas M. D. Anderson Cancer Center

Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.

Newswise: Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
4-Jun-2021 10:10 AM EDT
Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
University of Texas M. D. Anderson Cancer Center

Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
25-May-2021 5:35 PM EDT
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.

Released: 24-May-2021 10:00 AM EDT
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
University of Texas M. D. Anderson Cancer Center

Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes.

Newswise: New AI-based tool can find rare cell populations in large single-cell datasets
19-May-2021 3:55 PM EDT
New AI-based tool can find rare cell populations in large single-cell datasets
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have developed a first-of-its-kind AI tool to identify rare groups of biologically important cells from the noise of large, complex single-cell datasets. The new tool, called SCMER, can help reserachers gain new insights across many applications.

Newswise: Combination Therapy Achieves High Rates of Response for Patients with Acute Lymphoblastic Leukemia
18-May-2021 5:00 PM EDT
Combination Therapy Achieves High Rates of Response for Patients with Acute Lymphoblastic Leukemia
University of Texas M. D. Anderson Cancer Center

A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.

Newswise: Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
19-May-2021 12:05 PM EDT
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
University of Texas M. D. Anderson Cancer Center

A metabolic inhibitor drug, IACS-6274, developed by MD Anderson's Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.

Released: 17-May-2021 8:00 AM EDT
MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors
University of Texas M. D. Anderson Cancer Center

MD Anderson and Refuge have announced a strategic collaboration to advance new cell therapies for treating solid tumors. The agreement pairs Refuge's innovative technologies with the experience and capabilities of MD Anderson's Therapeutics Discovery division.

Newswise: NK cells with bispecific antibody show activity against lymphoma cells
12-May-2021 1:35 PM EDT
NK cells with bispecific antibody show activity against lymphoma cells
University of Texas M. D. Anderson Cancer Center

Cord blood-derived natural killer cells combined with a bispecific antibody displayed potent activity against lymphoma cells in a preclinical study led by MD Anderson researchers.

Newswise: Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
11-May-2021 8:00 AM EDT
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have discovered a new role for the DHODH enzyme in blocking a form of cell death called ferroptosis. Preclinical findings suggest that targeting DHODH could restore cell death and inhibit tumor growth.

Released: 11-May-2021 9:00 AM EDT
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
University of Texas M. D. Anderson Cancer Center

MD Anderson and the Broad Institute have launched a translational research platform to study rare cancers. The initiative will lead to a first-of-its-kind resource for the scientific community and will help to accelerate new therapies for patients with rare tumor types.

Newswise: Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
7-May-2021 12:10 PM EDT
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have developed a first-of-its-kind atlas of early-stage lung cancer and surrounding normal lung tissue. The single-cell map provides a valuable resource to learn about tumor development and find new therapeutic targets.

Newswise: Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
30-Apr-2021 3:25 PM EDT
Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
University of Texas M. D. Anderson Cancer Center

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.

Released: 29-Apr-2021 9:00 AM EDT
MD Anderson advances data collaboration through technology agreement with Syntropy
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today announced efforts to advance its capabilities to seamlessly connect basic science, translational and clinical research data for the benefit of patients through a technology collaboration with Syntropy and the Foundry platform.

Released: 14-Apr-2021 9:00 AM EDT
MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer
University of Texas M. D. Anderson Cancer Center

MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.

Newswise: Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Released: 12-Apr-2021 9:00 AM EDT
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
University of Texas M. D. Anderson Cancer Center

Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes

Newswise: MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
Released: 12-Apr-2021 9:00 AM EDT
MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
University of Texas M. D. Anderson Cancer Center

FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers (Abstract CT011); Combining dabrafenib and trametinib to treat BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG) shows significant antitumor activity; Therapeutics Discovery researchers identify key biomarker for metabolic inhibitor

Released: 8-Apr-2021 7:00 AM EDT
MD Anderson and TriSalus Life Sciences announce strategic research collaboration to evaluate treatment of solid tumors
University of Texas M. D. Anderson Cancer Center

MD Anderson and TriSalus announced a strategic research collaboration to evaluate the treatment of liver and pancreas tumors with the investigational therapy SD-101 in combination with immunotherapy using a novel delivery approach.

Released: 29-Mar-2021 10:00 AM EDT
MD Anderson’s Guillermina Lozano elected to Fellows of the AACR Academy
University of Texas M. D. Anderson Cancer Center

Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to describe the p53 tumor suppressor pathway, which is undermined in many cancers.

Newswise: New sequencing approach finds triple-negative breast cancers continue accumulating genetic changes during tumor growth
23-Mar-2021 11:30 AM EDT
New sequencing approach finds triple-negative breast cancers continue accumulating genetic changes during tumor growth
University of Texas M. D. Anderson Cancer Center

A new DNA sequencing approach developed by MD Anderson researchers overcomes technical challenges with earlier techniques to give deeper insights into breast cancer evolution.

Newswise: Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
11-Mar-2021 8:00 AM EST
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
University of Texas M. D. Anderson Cancer Center

A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.

Released: 9-Mar-2021 8:00 AM EST
MD Anderson’s Therapeutics Discovery division, Orionis Biosciences launch Project Helios to advance novel small-molecule cancer medicines
University of Texas M. D. Anderson Cancer Center

MD Anderson's Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a new collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.

Newswise: Collagen plays protective role during pancreatic cancer development
3-Mar-2021 2:20 PM EST
Collagen plays protective role during pancreatic cancer development
University of Texas M. D. Anderson Cancer Center

Contrary to long-held beliefs, new research finds that collagen in the tumor microenvironment may not promote cancer development but plays a protective role in controlling pancreatic cancer growth. The new findings could have important therapeutic implications.

Newswise: Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
Released: 18-Feb-2021 11:30 AM EST
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
University of Texas M. D. Anderson Cancer Center

The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.

Released: 10-Feb-2021 7:00 AM EST
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.

Released: 21-Jan-2021 11:40 AM EST
Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
University of Texas M. D. Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study published today in Cancer Cell.

Released: 19-Jan-2021 12:10 PM EST
Robin Roberts, Charles Barkley and TNT’s Ernie Johnson Jr. team up to #EndCancer on Feb. 4
University of Texas M. D. Anderson Cancer Center

An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University of Texas MD Anderson Cancer Center’s A Conversation with a Living Legend event. Robin Roberts, an anchor of “Good Morning America,” will join Emmy Award-winning sportscaster Ernie Johnson Jr. for a virtual fireside chat with a special guest appearance by 11-time NBA All-Star Charles Barkley.

Newswise: New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
15-Jan-2021 3:50 PM EST
New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have developed a new computational tool to accurately differentiate between cancer cells and normal cells when analyzing large single-cell RNA-sequencing data.

13-Jan-2021 8:00 AM EST
MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
University of Texas M. D. Anderson Cancer Center

MD Anderson and UroGen today announced a strategic three-year collaboration agreement to advance combination immunotherapy, delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer. The collaboration will work through MD Anderson's immunotherapy platform to design pre-clinical and clinical studies.

7-Jan-2021 10:05 AM EST
Mediterranean Diet May Decrease Risk of Prostate Cancer Progression for Men on Active Surveillance
University of Texas M. D. Anderson Cancer Center

In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.

Released: 6-Jan-2021 4:05 PM EST
MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

Newswise: Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
4-Jan-2021 9:55 AM EST
Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
University of Texas M. D. Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis (PC), a specific form of metastatic gastric cancer, defined the extensive cellular heterogeneity and identified two distinct subtypes correlated with patient survival.

Newswise: Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
4-Jan-2021 9:50 AM EST
Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
University of Texas M. D. Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumor immune response.

Newswise: Novel antibody-drug conjugate shows promising early results in rare blood cancer
Released: 7-Dec-2020 10:35 AM EST
Novel antibody-drug conjugate shows promising early results in rare blood cancer
University of Texas M. D. Anderson Cancer Center

A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.

Newswise: Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia
Released: 7-Dec-2020 9:00 AM EST
Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia
University of Texas M. D. Anderson Cancer Center

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

5-Dec-2020 5:05 PM EST
CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
University of Texas M. D. Anderson Cancer Center

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

Newswise: New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability
20-Nov-2020 5:05 PM EST
New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability
University of Texas M. D. Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the enolase enzyme.

18-Nov-2020 11:00 AM EST
A Conversation With a Living Legend honoring Admiral William H. McRaven raises $1 million
University of Texas M. D. Anderson Cancer Center

The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News' Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.

18-Nov-2020 8:30 AM EST
MD Anderson and Obsidian Therapeutics announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division.

Released: 13-Nov-2020 2:55 PM EST
Sherry Adkins receives Brown Foundation Award for Excellence in Oncology Nursing
University of Texas M. D. Anderson Cancer Center

Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing, MD Anderson's highest nursing honor.

11-Nov-2020 12:15 PM EST
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
University of Texas M. D. Anderson Cancer Center

Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .


Showing results

150 of 1385

close
0.45923